makes sense but we should probably confirm with uptodate or another resource
Per UpToDate:
• Within the United States, approach to treatment of leprosy aligns with the United States National Hansen’s Disease Program (NHDP), as follows:
-For patients with tuberculoid (paucibacillary [PB]; TT, BT) disease, we suggest treatment with dapsone and daily rifampin for 12 months (Grade 2C).
-For patients with lepromatous (multibacillary [MB]; LL, BL, BB) disease, we suggest treatment with dapsone, daily rifampin, and clofazimine for 24 months (Grade 2C).
• Outside the United States, countries follow the World Health Organization (WHO) approach, as follows:
-For patients with tuberculoid (PB; TT, BT) disease, treatment consists of dapsone, monthly rifampin, and clofazimine for 6 months.
-For patients with lepromatous (MB; LL, BL, BB) disease, treatment consists of dapsone, monthly rifampin, and clofazimine for 12 months.
so this should also be changed to 12 months per uptodate?
Yeah looks like 12 months would be right. Overall the two leprosy treatment cards are probably on the lower-yield end of things? Maybe I just put the contrasting information from UpToDate in the extra section?